Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    2019-004400-35
Previous Study | Return to List | Next Study

Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) (ReSScue)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04300426
Recruitment Status : Recruiting
First Posted : March 9, 2020
Last Update Posted : April 19, 2021
Sponsor:
Collaborators:
South-Eastern Norway Regional Health Authority
Haukeland University Hospital
St. Olavs Hospital
University Hospital of North Norway
Information provided by (Responsible Party):
Anna-Maria Hoffmann-Vold, Oslo University Hospital

Brief Summary:
This study evaluates the effect of intestinal microbiota therapy on gastro-intestinal symptoms in patients with systemic sclerosis (SSc). This is a mulicenter randomized controlled trial conducted at university hospitals in Oslo, Tromsø, Bergen and Trondheim in Norway. In part A1, half of the patients will receive active substance (intestinal microbiota cultured in the lab - "ACHIM") in the small intestine twice by gastroduodenoscopy, the other half will receive placebo. The primary outcome will be measured on week 12 by patient reported outcome measures. In part A2, all participants receive ACHIM at week 12, with an 8 week follow-up for all. A step-wise follow-up will be done in part B up to 16 weeks after week 20 until the last participant finish week 20 visit, which is defined as end of study.The blind from the first intervention will not be opened before end of study.

Condition or disease Intervention/treatment Phase
Systemic Sclerosis Drug: "ACHIM" as solute (10^9 intestinal microbes/ml) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The 20-week study period consists of a 12-week induction phase (Part A1), with randomized, double-blind parallel group interventions by endoscopic infusions at weeks 0 and 2, and an 8-week maintenance phase (Part A2) where all participants receive one single open label endoscopic infusion on week 12. Additionally, all participants who complete the 20-week study period are followed for a maximum 16 weeks monitoring period (Part B) to obtain longer-term data on safety and durability of intervention effects.
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Masking will apply for the whole duration of study until end of study defined as week 20 visit for the last participant.
Primary Purpose: Treatment
Official Title: Aiming to Reduce Disease-related Gastrointestinal Symptoms in Systemic Sclerosis by Repeat Intestinal Infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Randomized, Double-blind Placebo-controlled 20 Week Study
Actual Study Start Date : September 24, 2020
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scleroderma

Arm Intervention/treatment
Experimental: ACHIM by gastroduodenoscopy

Intestinal microbiota (acronym ACHIM - anaerobically cultured human intestinal microbiota) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml, containing approximately 10^9 bacteria / ml.

Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study.

Drug: "ACHIM" as solute (10^9 intestinal microbes/ml)
Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
Other Name: Fecal microbiota transplantation

Placebo Comparator: Placebo by gastroduodenoscopy

ACHIM culture media (no bacteria) will be administered by gastroduodenoscope twice (given at baseline and study-week 2). Each with volume 30 ml.

Primary outcome measured at week 12. At week 12 an open label administration of ACHIM to all participants. Thereafter an 8 (+16) week period observation. Blind from the first intervention will be maintained through-out the duration of the study.

Drug: "ACHIM" as solute (10^9 intestinal microbes/ml)
Culture of intesinal microbiota originally derived from a healthy subject are administered to a person with presumed dysbiotic intestinal symptoms with an objective to treat these symptoms.
Other Name: Fecal microbiota transplantation




Primary Outcome Measures :
  1. • Change from baseline to week 12 in UCLA GIT score item diarrhea or bloating, depending which was the worst symptom at baseline evaluated separately for each patient [ Time Frame: baseline to week 12 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The bloating scale is scored on a Visual Analog Scale from 0 (better) to 3 (worse) and the diarrhea scale from 0 (better) to 2.5 (worse). Change=(week12 score-baseline score)


Secondary Outcome Measures :
  1. • Safety and tolerability assessed by adverse event (AE) monitoring, physical examination and clinical laboratory testing from baseline to the end of the study period [ Time Frame: • Over the study period of 20 (+16) weeks ]
    • Registration of number of adverse events adverse event (AE), assessment of physical examination and clinical laboratory testing by standardized assessments and sampling

  2. • Change from baseline to week 12 in total UCLA GIT score [ Time Frame: baseline, week 6 and week 12. ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The total scale is scored on a Visual Analog Scale from 0 (better) to 3 (worse). Change=(week12 score-baseline score)

  3. • Change from baseline to week 12 in UCLA GIT score item diarrhea [ Time Frame: baseline to week 12 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The diarrhea scale is scored on a Visual Analog Scale from 0 (better) to 2.5 (worse) . Change=(week12 score-baseline score)

  4. • Change from baseline to week 12 in UCLA GIT score item bloating [ Time Frame: baseline to week 12 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The bloating scale is scored on a Visual Analog Scale from 0 (better) to 3 (worse) . Change=(week12 score-baseline score)


Other Outcome Measures:
  1. • Change from baseline to week 12 in Faecal incontinence quality of life scale [ Time Frame: baseline to weeks 12 ]
    Fecal Incontinence Quality-of-Life Scale is a validated patients reported outcome divided in four subscales all rated from 1-4 (5,6) by 1 having lowest quality of life. Change=(week12 score-baseline score)

  2. • Change from baseline to week 12 in UCLA GIT score item reflux [ Time Frame: baseline to week 12 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The reflux scale is scored on a Visual Analog Scale from 0 (better) to 3 (worse) . Change=(week12 score-baseline score)

  3. • Change from baseline to week 12 in UCLA GIT score item fecal soilage [ Time Frame: baseline to week 12 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The fecal soilage scale is scored on a Visual Analog Scale from 0 (better) to 3 (worse) . Change=(week12 score-baseline score)

  4. • Change from baseline to week 12 in UCLA GIT score item constipation [ Time Frame: baseline to week 12 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The constipation scale is scored on a Visual Analog Scale from 0 (better) to 2.5 (worse) . Change=(week12 score-baseline score)

  5. • Change from baseline to week 12 in UCLA GIT score item emotional wellbeing [ Time Frame: baseline to week 12 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The emotional wellbeing scale is scored on a Visual Analog Scale from 0 (better) to 3 (worse) . Change=(week12 score-baseline score)

  6. • Change from baseline to week 12 in UCLA GIT score item social participation [ Time Frame: baseline to week 12 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The social participation scale is scored on a Visual Analog Scale from 0 (better) to 3 (worse) . Change=(week12 score-baseline score)

  7. • Change from baseline to week 12 in • Change from baseline to week 12 in HAQ-DI scores [ Time Frame: baseline to week 12 ]
    The HAQ-DI is a patient reported outcome measuring generic health status and quality of life scale ranging from 0 to 3, with no difficultie (scale 0) up to major difficulties (scale 3). Change=(week12 score-baseline score)

  8. • Change from baseline to week 12 in VAS Fatigue scale [ Time Frame: baseline to week 12 ]
    The fatigue scale measures fatigue representing how the participant feel, along a visual analogue line that extends between "not at all tired" (0) to "extremely tired" (10). Change=(week12 score-baseline score)

  9. • Change from baseline to week 12 in ScleroId score [ Time Frame: baseline to week 12 ]
    The ScleroId has 10 SSc specific questionnes all along a visual analogue line that extends between "none" (0) to "extreme" (10) with a maximum score of 100. Change=(week12 score-baseline score)

  10. • Change from baseline to weeks 2, 6 and 12 in overall faecal microbiome composition measured by 16sRNA based methods [ Time Frame: baseline to week 2, 6 and 12 ]
    16sRNA based methods measure the fecal microbiota composition and will be assessed at 4 timepoints. Changes from baseline to week 2,6 and 12 will be assessed.

  11. • Change from baseline to week 12 in saliva, skin and urine microbiome measured by 16sRNA based methods [ Time Frame: baseline to week 12 ]
    16sRNA based methods measure the microbiota composition and will be assessed at 4 timepoints. Changes from baseline to week 2,6 and 12 will be assessed.

  12. • Change from baseline to weeks 2, 6 and 12 in immunoglobulin bound fraction of the overall faecal microbiome [ Time Frame: • Baseline up to week 2, 6 and 12 ]
    16sRNA based methods measure the fecal microbiota composition which is Ig coated and will be assessed at 4 timepoints. Changes from baseline to week 2,6 and 12 will be assessed.

  13. • Change from baseline to week 12 in gastrointestinal transit time and contractions evaluated by SmartPill technology along with registration of stool frequency and consistency by Bristol Stool Scale [ Time Frame: Baseline to week week 12 ]
    In a subgroup of patients SmartPill technology assesses gastrointestinal transit time. Chenges will be assessed frombaseline to week 12

  14. • Change from baseline to weeks 6 and 12 in peripheral blood B cell and T cells (as evaluated by receptor sequencing, proteomics and cellular phenotyping) and content of soluble molecules [ Time Frame: baseline to week 6 and 12 ]
    Blood samples will be assessed for changes from baseline to weeks 6 and 12

  15. • Change from baseline to weeks 2 and 12 in the architecture and cellular composition of duodenal biopsy specimens (including characterization of cellular surface markers, proteomics, metabolomics and immune cell receptor sequencing [ Time Frame: Baseline to week 2 and 12 ]
    Tissue samples will be assessed from skin and intestines and changes from baseline to weeks 2 and 12 determined

  16. • Change from baseline to week 12 in skin properties evaluated by elastography and ultrasonographic skin thickness [ Time Frame: week 12 to week 12 ]
    Elastography assess skin properties and will be assessed in a subset of patients at baseline and week 12

  17. • Change from baseline to week 12 in Health-related Quality of Life assessed by EQ-5D [ Time Frame: baseline to week 12 ]
    The EQ-5D is a generic health status and quality of life scale. The respondents evaluate their overall health status using the visual analogue scalend scales of 1-3 with higher values having worse health. Change=(week12 score-baseline score)

  18. • Change from week 12 through week 20 in all participants, and up to week 36 in a subset of participants in UCLA GIT score item diarrhea or bloating, depending which was the worst symptom at the baseline evaluated separately for each patient [ Time Frame: week 12 to 20 and 36 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The diarrhea scale is scored on a Visual Analog Scale from 0 (better) to 2.5 (worse), the bloting from 0-3. Change=(week20 score-week 12 score)

  19. • Follow changes of UCLA total GIT score from week 12 through week 20 in all participants, and up to week 36 in a subset of participants [ Time Frame: week 12 to 20 and 36 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The total scale is scored on a Visual Analog Scale from 0 (better) to 3 (worse). Change=(week20 score-week 12 score)

  20. • Follow changes in mean of HAQ-DI; VAS Fatigue; ScleroId score; and patient reported global assessment from week 12 through week 20 in all participants, and up to week 36 in a subset of participants [ Time Frame: week 12 to 20 and 36 ]
    See endpoints explained above for the different outcome measures and explanations

  21. • Assess changes of overall faecal microbiome composition measured by 16sRNA based methods from week 12 through week 20 in all participants, and up to week 36 in a subset of participants [ Time Frame: week 12 to 20 and 36 ]
    16sRNA based methods measure the microbiota composition and will be assessed at week 12, 20 and partly 36. Changes from to week 12 to week 20 and in a subset to week 36 will be assessed.

  22. • Assess change of saliva, skin and urine microbiome measured by 16sRNA based methods from week 12 through week 20 in all participants [ Time Frame: week 12 to 20 ]
    16sRNA based methods measure the microbiota composition and will be assessed at week 12 and 20. Changes from week 12 to week 20 will be assessed.

  23. • Assess change in peripheral blood B cell and T cells and content of soluble molecules from week 12 through week 20 in all participants, and up to week 36 in a subset of participants [ Time Frame: week 12 to 20 and 36 ]
    Blood samples will be assessed for changes from week 12 to week 20 and 36 in a subset

  24. • Assess changes in upper GIT scores from week 12 to 20 and determine potential associations to the architecture and cellular composition of oesophagus biopsy specimens [ Time Frame: week 12 to 20 ]
    The UCLA GIT score is a validated patient reported outcome measure capturing and grading GI symptoms related to SSc. The reflux scale is scored on a Visual Analog Scale from 0 (better) to 3 (worse) . Change=(week20 score-week 12 score) and assess changes in association with øsophagus biopsies

  25. • Assess change from week 12 to 20 in Health-related Quality of Life assessed by EQ-5D from week 12 through week 20 in all participants, and up to week 36 in a subset of participants [ Time Frame: week 12 to 20 and 36 ]
    The EQ-5D is a generic health status and quality of life scale. The respondents evaluate their overall health status using the visual analogue scalend scales of 1-3 with higher values having worse health. Change=(week20 and 36 score-week 12 score)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participant must be 18 to 85 years of age inclusive, at the time of signing the informed consent.
  2. Participants must have been clinically diagnosed with SSc by a rheumatologist having experience with the disease.
  3. Participants must have disease characteristics that fulfill the 2013 ACR/EULAR classification criteria for SSc.
  4. Participants must be able to understand and follow trial procedures including completion of questionnaires regarding Patient Reported Outcome measures, such as the Norwegian version of the UCLA GIT V2.0 score.
  5. Participants must have moderate to severe SSc-related lower GI symptoms at time of inclusion, as defined by UCLA GIT score values of ≥1.01 for bloating and/or ≥0.50 for diarrhea at the screening visit.
  6. Male and female
  7. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

  • Medical Conditions

    1. Cardiovascular diseases, any of the following

      1. Severe hypertension, uncontrolled under treatment (≥160/100 mmHg), within 6 month of Visit 1
      2. Myocardial infarction within 6 months of Visit 1
      3. Unstable cardiac angina within 6 months of Visit 1
    2. Lung disease with impaired respiratory function, any of the following

      1. Forced Vital Capacity (FVC) < 50% of expected reference value within 12 month of Visit 1
      2. Diffusing lung capacity for carbon monoxide (DLCO) < 40% of expected reference value within 12 month of Visit 1
      3. LTOT or lung-tx
    3. Significant pulmonary hypertension, any of the following

      1. Previous clinical or echocardiographic evidence of significant right heart failure
      2. History of right heart catheterisation showing a cardiac index ≤ 2 l/min/m²
    4. History of thrombotic event (including stroke and transient ischemic attack) within 12 months of Visit 1
    5. Severe anemia with Hb < 8.0 g/l within 4 weeks prior to Visit 1. Repeat testing of Hb is allowed.
    6. Bleeding risk, any of the following

      1. History of hemorrhagic central nervous system (CNS) event within 12 months of Visit 1.
      2. Known genetic predisposition to bleeding
      3. Platelet counts < 50 x 109/l
    7. Chronic liver disease or gastro-intestinal condition, any of the following

      1. Primary biliary cholangitis
      2. Primary sclerosing cholangitis
      3. Decompensated chronic liver disease
      4. Inflammatory bowel disease
      5. Celiac disease treated for less than 12 months.
    8. Gastro-intestinal surgery performed within the within 12 months of Visit 1
    9. Hepatic dysfunction, as defined as AST, ALT or bilirubin levels >3 times the Upper limit of normal range (x ULN) within 4 weeks prior to Visit 1. Repeat testing of AST, ALT and bilirubin are allowed in participants with no prior history of hepatic dysfunction.
    10. Chronic renal insufficiency, with estimated Glomerular Filtration Rate (eGFR) < 30.
    11. Active digital ulcers within 4 weeks of Visit 1.
    12. Anaphylactic food allergy.
    13. Eating disorder diagnosed by a physician
    14. Other diseases or conditions that may interfere with testing procedures (for example inability to conduct gastroduodenoscopy) or in the judgment of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial (for example severe GI symptoms due to other diseases than SSc).

      Prior/Concomitant Therapy

    15. Any antibiotic therapy within 3 months of Visit 1
    16. Prednisone >10 mg/day or equivalent within 4 weeks prior to Visit 1
    17. Cyclophosphamide or rituximab treatment within 6 months prior to Visit 1
    18. Unstable background monotherapy with any of the following therapeutics; mycophenolate mofetil/sodium, methotrexate, azathioprine, tocilizumab, abatacept, leflunomide, tacrolimus, tofacitinib and cyclosporine A. Participants have to be on stable monotherapy with any of these medications for at least 6 months prior to visit 1
    19. Combined therapy of two or more of the following therapeutics: mycophenolate mofetil/sodium, methotrexate, azathioprine, tocilizumab, abatacept, leflunomide, tacrolimus, tofacitinib and ciclosporine A within at least 8 weeks prior to visit 1.
    20. Need for full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors or heparin)
    21. Previous hematopoietic stem cell transplantation (HSCT) within 12 months of Visit 1, or HSCT planned within 12 months after Visit 1.
    22. Other investigational therapy received within 1 month or 6 half-lives (whichever was greater) prior to screening visit.

      Prior/Concurrent Clinical Study Experience

    23. Prior participation in FMT study in the last 12 months. Diagnostic assessments
    24. Abnormal coagulation parameters as defined as International normalised ratio (INR) >2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by >1.5 x ULN at Visit 1 Other Exclusions
    25. Women who are pregnant, nursing, or who plan to become pregnant while in the trial. (Women of child bearing potential should be tested with Hcg (urine or serum). Woman of child bearing potential if not using highly efficient contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04300426


Contacts
Layout table for location contacts
Contact: Maylen Carstens, Study nurse 91502770 ext 47 maylno@ous-hf.no
Contact: Anna-Maria Hoffmann-Vold, MD, PhD 91502770 ext 47 a.m.hoffmann-vold@medisin.uio.no

Locations
Layout table for location information
Norway
Haukeland University Hospital Not yet recruiting
Bergen, Norway
Contact: Tove Hatletveit, Nurse       tove.hatletveit@helse-bergen.no   
Contact: Anne-Kristine Halse, MD       anne.kristine.hjorteseth.halse@helse-bergen.no   
Principal Investigator: Anne-Kristine H Halse, MD PhD         
Oslo University Hospital Recruiting
Oslo, Norway
Contact: Maylen Nordgård Carstens, Nurse    +4791700631    maylno@ous-hf.no   
Contact: Håvard Fretheim, MD       havard.fretheim@ous-hf.no   
Principal Investigator: Håvard Fretheim, MD         
University hospital of North Norway Not yet recruiting
Tromsø, Norway
Contact: Inger-Lise Knutsen, Nurse       Inger-Lise.Knutsen@unn.no   
Contact: Gunnstein Bakland, MD       Gunnstein.Bakland@unn.no   
Principal Investigator: Gunnstein Bakland, MD PhD         
St. Olavs hospital, Trondheim university hospital Not yet recruiting
Trondheim, Norway
Contact: Tone Karaaslan, Nurse       tone.karaaslan@stolav.no   
Contact: Alvilde Dhainaut, MD       alvilde.dhainaut@ntnu.no   
Principal Investigator: Alvilde Dhainaut, MD         
Sponsors and Collaborators
Oslo University Hospital
South-Eastern Norway Regional Health Authority
Haukeland University Hospital
St. Olavs Hospital
University Hospital of North Norway
Investigators
Layout table for investigator information
Principal Investigator: Anna-Maria Hoffmann-Vold, MD, PhD Oslo University Hospital
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Anna-Maria Hoffmann-Vold, National PI, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT04300426    
Other Study ID Numbers: 2019-004400-35
First Posted: March 9, 2020    Key Record Dates
Last Update Posted: April 19, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The investigators plan to publish the protocol and statistical analysis plan separately. The IPD will be published according to relevant legislation and as required by publishing authority.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Not known yet.
Access Criteria: Not known yet.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Sclerosis
Pathologic Processes
Connective Tissue Diseases
Skin Diseases